Small Cell Lung Cancer, SCLC – Treatment with an approved drug, Onivyde, shows efficacy
Many small cell lung cancer patients rapidly relapse due to the aggressive nature of the disease. While the current standard of care in the second-line
Lung cancer patients, heard already about Capmatinib?
The Food and Drug Administration, the FDA, has granted capmatinib a “breakthrough therapy” designation as a first-line treatment for Non-Small Cell Lung Cancer (NSCLC) patients
This Trial Achieved Complete Disappearance of Disease in Metastatic Kidney Cancer
The main therapeutic objectives in treating metastatic disease are prolonging life (also called “Survival”) and Quality of Life (QoL), knowing the disease will stay in
Pancreatic Cancer – between 2 to 3 times survival with SM-88
Background The National Comprehensive Cancer Network, NCCN, is the health body which sets the world guidelines in treating cancer. The NCCN recommends clinical trials as
New drug may become the new standard of care for patients with small cell lung cancer, SCLC
Don’t miss opportunities to get drugs like this in a clinical trial setting! Why? Lurbinectedin monotherapy as a second-line therapy in patients with small cell
A novel drug gets Breakthrough Designation in combination with Opdivo® in Melanoma
Background Bempegaldesleukin, NKTR-214, and nivolumab, Opdivo, was granted breakthrough deisgnation by the FDA for the first line treatment of patients with previously untreated unresectable or
Potential promise with T cell immunotherapy for pancreatic cancer
Background Pancreatic cancer is one of the most challenging types of cancer to treat, but new therapy using the body’s own immune system is providing
The European authority adopted positive opinion for new combination as first line treatment for stage IV metastatic lung cancer
About Non Small Cell Lung Cancer, NSCLC Lung cancer is the leading cause of cancer death globally. Each year 1.76 million people die as a
New hope for ovarian cancer patients – regardless of BRCA status
Background – The first standard treatment for advanced ovarian cancer patients is platinum-based chemotherapy. If the patient responds to this chemotherapy, she will continue to
Not only for MSI-H! A combination of two approved drugs is in Phase III trial for MSS colorectal cancer
Background – The combination of regorafenib (Stivarga) and nivolumab (Opdivo) will be compared with regorafenib alone in a phase III trial of patients with microsatellite
Is an immunotherapy approved drug on its way to treat Small Cell Lung Cancer, SCLC?
About Orphan Drug and the “CASPIAN” – The FDA has granted an orphan drug designation to “Durvalumab” (“Imfinzi”) for the treatment of patients with small
We Are Proud To Be At the Forefront of Personalized Medicine to Update You on This Novel Cancer Drug Approval
About the approval, the studies and the drug, entrectinib – The first regulatory approval has been granted to entrectinib (Rozlytrek) in Japan for the treatment
